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Abstract: In Duchenne muscular dystrophy (DMD), a dysregulated extracellular matrix (ECM)
directly exacerbates pathology. Glucocorticoids are beneficial therapeutics in DMD, and have
pleiotropic effects on the composition and processing of ECM proteins in other biological contexts.
The synthesis and remodelling of a transitional versican-rich matrix is necessary for myogenesis;
whether glucocorticoids modulate this transitional matrix is not known. Here, versican expression
and processing were examined in hindlimb and diaphragm muscles from mdx dystrophin-deficient
mice and C57BL/10 wild type mice. V0/V1 versican (Vcan) mRNA transcripts and protein levels were
upregulated in dystrophic compared to wild type muscles, especially in the more severely affected
mdx diaphragm. Processed versican (versikine) was detected in wild type and dystrophic muscles,
and immunoreactivity was highly associated with newly regenerated myofibres. Glucocorticoids
enhanced C2C12 myoblast fusion by modulating the expression of genes regulating transitional
matrix synthesis and processing. Specifically, Tgfβ1, Vcan and hyaluronan synthase-2 (Has2) mRNA
transcripts were decreased by 50% and Adamts1 mRNA transcripts were increased three-fold by
glucocorticoid treatment. The addition of exogenous versican impaired myoblast fusion, whilst
glucocorticoids alleviated this inhibition in fusion. In dystrophic mdx muscles, versican upregulation
correlated with pathology. We propose that versican is a novel and relevant target gene in DMD,
given its suppression by glucocorticoids and that in excess it impairs myoblast fusion, a process key
for muscle regeneration.
Keywords: Duchenne muscular dystrophy; fibrosis; glucocorticoids; myogenesis; mdx mouse; versican
1. Introduction
Duchenne muscular dystrophy (DMD) is a fatal hereditary disease affecting ~1:3500 boys, with
glucocorticoid therapy being the only treatment with clinical efficacy [1]. DMD is caused by mutations
in the dystrophin (DMD) gene, which renders dystrophic skeletal muscles vulnerable to ongoing
contraction-induced injury, resulting in excessive inflammation, impaired regeneration and fibrosis [2].
Whilst fibrosis is usually thought of as a disease endpoint, it is important to note that endomysial
extracellular matrix (ECM) accumulation precedes overt muscle degeneration in DMD [3], and is
thought to actively contribute to the degeneration of dystrophic muscles [4–6].
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The composition and processing of the ECM influences global cell behaviour, including cellular
processes necessary for effective muscle repair [7–9]. Aberrant ECM synthesis and processing is
observed in dystrophic muscles from patients with DMD [10] and in mdx mice [11], compromising
regenerative myogenesis and exacerbating inflammatory processes [12]. TGF-β is considered to be
a key cytokine driving fibrosis in DMD [13], and its levels are elevated in dystrophic muscles and in
circulation [14].
The mature ECM of normal skeletal muscle is composed of glycoproteins, collagens
and proteoglycans containing heparan sulphate and chondroitin sulphate/dermatan sulphate
glycosaminoglycan (GAG) side chains [15]. Endomysial fibrosis in DMD is associated with the
increased expression of not only mature ECM proteins [16,17], but also transitional ECM proteins
such as hyaluronan and versican [18]. These transitional matrix proteins, through their synthesis
and remodelling, regulate cell behaviour during normal development and regeneration, as well as
functioning as a scaffold for mature ECM deposition [8,19]. ECM proteases are also upregulated in
dystrophic muscles [20]. Strategies to limit aberrant ECM synthesis and remodelling in DMD are
of therapeutic interest. Given the importance of a transitional matrix in tissue repair, versican is
an especially relevant ECM protein [18].
Versican is a chondroitin sulphate proteoglycan (CSPG) [19], localised to pericellular regions of
the basement membranes and interstitial matrices [9,21,22]. In skeletal muscle, the V0 and V1 splice
variants of versican are the most abundant [9]. V0/V1 versican is comprised of the G1 and G3 globular
domains at the N- and C-terminus respectively, with each of their core proteins sharing a common
GAG-β domain and V0 versican containing an additional GAG-α domain. Chondroitin sulphate
moieties on V0/V1 versican bind growth factors, cytokines and adhesion molecules, such as CD44
(cluster of differentiation 44), to regulate downstream signalling pathways [23]. The C- and N-termini
of versican bind various ECM molecules [24], including hyaluronan [25], a large non-proteinaceous
GAG of variable size which has been linked to myogenesis and muscle growth [8,26]. Hyaluronan is
synthesised by hyaluronan synthases (HAS) and degraded by hyaluronidases (HYAL), with HAS2,
HYAL1 and HYAL2 being the predominant skeletal muscle isoforms [26].
Recent studies have highlighted the role of versican in myoblast proliferation and myotube
formation, processes critical for regenerative myogenesis [9,27]. In developing chick skeletal muscle,
versican is synthesised early in myogenesis [27] and is localised to the pericellular matrix of developing
myotubes [28]. V1 versican is cleaved at the Glu441-Ala442 peptide bond within the GAG-β domain by
specific A Disintegrin-like And Metalloproteinase Domain with ThromboSpondin-1 repeats (ADAMTS)
proteoglycanases [29], which include ADAMTS1, -4, -5, -9, -15 and -20 [30], and presumably ADAMTS8,
however this has not yet been proven [31]. This produces the bioactive G1-DPEAAE fragment known
as versikine [19], which in other biological contexts can be pro-apoptotic [32] or pro-inflammatory [33].
Using C2C12 myoblasts as an in vitro model of regenerative myogenesis, we have shown that the
processing of a versican and hyaluronan rich transitional, pericellular matrix by ADAMTS5 or -15
facilitated myotube formation [9].
Glucocorticoids delay disease progression in DMD by improving muscle strength, respiratory
function, and increasing ambulation by up to four years [34,35]. These beneficial effects may be due
to membrane stabilisation, decreased muscle necrosis and fibrosis, modulation of inflammation,
and/or improved regeneration [12,36]. In dystrophic mdx mice, high dose treatment with the
glucocorticoid deflazacort increased the proliferation and/or fusion of muscle precursor cells during
myotube formation following crush injury, as well as enhancing the growth of intact myotubes [37].
More recently, when mdx mice were treated with prednisone or VBP15 (vamorolone; a dissociative
glucocorticoid [38]) TGF-β related networks were suppressed, this included reduced gene expression
of various collagen isoforms (1A1, 3A1 and 6A1), leading to improved muscle repair [12]. In vitro,
glucocorticoids also enhanced myotube formation in primary wild type and dystrophic mdx myoblasts,
as well as in C2C12 cells [39,40].
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Given the importance of transitional matrix synthesis and remodelling for myofibre formation and
that glucocorticoids can enhance myogenic differentiation [1,8,41], the effects of glucocorticoids on the
ECM during myogensis and myoblast differentiation should be better characterised. In other disease
models associated with a heightened pro-inflammatory state, glucocorticoids do modulate ECM
composition and degradation with the specific effects being tissue and context dependent. In cultured
rat mesangial cells, glucocorticoids decreased secreted and cell associated chondroitin sulphate and
dermatan sulphate proteoglycan content by 50% [42]. In cultured airway fibroblasts stimulated with
serum, glucocorticoids decreased versican gene and protein expression by 50% [43]. Hyaluronan
content in skin and dermal fibroblasts was also reduced following glucocorticoid treatment [44],
due to decreased Has2 mRNA transcription and stability, and thus reduced hyaluronan synthesis [45].
Given their clinical usage in DMD and the ECM expansion observed in dystrophic muscles,
understanding the transitional ECM gene targets regulated by glucocorticoids in skeletal muscle
cells is an important step towards improving therapeutic outcomes for strategies targeting fibrosis
in dystrophy.
Here, we show that V0/V1 versican mRNA transcript abundance and protein levels are elevated
in diaphragm and hindlimb tibialis anterior (TA) muscles from dystrophic mdx mice when compared
to C57BL/10 wild type mice. We identify a novel mechanism mediating the glucocorticoid stimulated
increase in myoblast fusion and myotube formation in C2C12 cells. Specifically, in differentiating
myoblasts, low doses of glucocorticoids (25 or 100 nM dexamethasone) modulated the expression of
genes associated with the synthesis and processing of a versican–hyaluronan rich transitional matrix.
This effect is dependent on versican, as glucocorticoid treatment improved myotube formation in the
presence of excess versican. As a whole, these findings offer novel insight into the relevance of versican
in dystrophic skeletal muscle pathology.
2. Results
2.1. Versican Expression Is Increased in Dystrophic Muscles and Correlate with the Severity of Pathology
The pathology of TA muscles from adult mdx mice is moderate compared to the human
disease. Specifically, in hindlimb muscles from mdx mice there is minimal fibrosis, lower levels of
inflammation and more effective regeneration as indicated by the presence of centrally nucleated
fibres [46] (Figure 1B); although, muscle strength is compromised [47]. The pathology of mdx diaphragm
muscles is more representative of DMD, with greatly impaired contractile function and high levels
of endomysial fibrosis [48,49] (Figure 1D). V0/V1 Vcan mRNA transcript abundance was greater
in dystrophic compared to wild type muscles (Figure 1I). To support this gene expression data,
the immunoreactivity of full length V0/V1 versican and its cleaved bioactive fragment, versikine,
was assessed in TA and diaphragm muscle cross-sections from mdx and wild type mice (Figure 2).
V0/V1 versican protein levels were upregulated in TA and diaphragm muscles from mdx
mice (Figure 2B,D) compared to wild type mice (Figure 2A,C, and as quantified in Figure 2I).
In concordance with the more severe pathology, versican immunoreactivity was greatest in the mdx
diaphragm. In dystrophic muscles, versican staining was localised to regions of mononuclear infiltrate,
which includes myoblasts, inflammatory cells and fibroblasts (Figure 2B,D; as indicated with a white
asterisk). Versican staining was also associated with endomysial fibrosis in TA (Figure 3A–D) and
diaphragm muscles (Figure 2D).
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Figure 1. Muscle architecture and fibrosis in wild type and mdx mice. (A–D) Muscle architecture can 
be determined from the H and E-stained muscle cross-sections, and (E–H) areas of fibrosis can be 
observed by examining wheat germ agglutinin (WGA) stained cross-sections. (I) Versican (V0/V1 
Vcan) mRNA transcript abundance was increased in mdx compared to wild type mice (* p = 0.026; 
main effect genotype; 2-way general linear model (GLM) ANOVA). Arrows denote areas of fibrosis 
and mononuclear infiltrate. Gene expression analysis was determined from n = 3 wild type mice and 
n = 3 mdx mice. Scale bar = 100 µm. Error bars = S.E. 
Remodelling of V1 versican by ADAMTS proteoglycanases (e.g., ADAMTS1, -5 and -15) yields 
the bioactive versikine fragment [19]. Versikine immunoreactivity was predominantly localised to 
the pericellular region of myofibres, and did not differ between dystrophic and wild type TA or 
diaphragm muscles (Figure 2E–H, and as quantified in Figure 2J). In mdx TA and diaphragm muscle 
cross-sections, versikine staining was also associated with regions of mononuclear infiltrate  
(Figure 2F,H; as indicated with a white asterisk). When this association of versikine with 
mononuclear infiltrate was further interrogated in mdx TA muscle cross-sections by specifically 
assessing areas of regeneration, high levels of versikine immunoreactivity were co-localised with 
desmin positive, newly regenerated myofibres (Figure 3E–H). Furthermore, nuclear localisation of 
versikine (but not versican) was observed in muscle fibres and mononuclear infiltrate (Figure 3I,J). 
Figure 1. Muscle architecture and fibrosis in wild type and mdx mice. (A–D) Muscle architecture
can be determined from the H and E-stained muscle cross-sections, and (E–H) areas of fibrosis can
be observed by examining wheat germ agglutinin (WGA) stained cross-sections. (I) Versican (V0/V1
Vcan) mRNA transcript abundance was increased in mdx compared to wild type mice (* p = 0.026;
main effect genotype; 2-way general linear model (GLM) ANOVA). Arrows denote areas of fibrosis
and mononuclear infiltrate. Gene expression analysis was determined from n = 3 wild type mice and n
= 3 mdx mice. Scale bar = 100 µm. Error bars = S.E.
Remodelling of V1 versican by ADAMTS proteoglycanases (e.g., ADAMTS1, -5 and -15) yields
the bioactive versikine fragment [19]. Versikine immunoreactivity was predominantly localised to the
pericellular region of myofibres, and did not differ between dystrophic and wild type TA or diaphragm
muscles (Figure 2E–H, and as quantified in Figure 2J). In mdx TA and diaphragm muscle cross-sections,
versikine staining was also associated with regions of mononuclear infiltrate (Figure 2F,H; as indicated
with a white asterisk). When this association of versikine with mononuclear infiltrate was further
interrogated in mdx TA muscle cross-sections by specifically assessing areas of regeneration, high levels
of versikine immunoreactivity were co-localised with desmin positive, newly regenerated myofibres
(Figure 3E–H). Furthermore, nuclear localisation of versikine (but not versican) was observed in muscle
fibres and mononuclear infiltrate (Figure 3I,J).
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Figure 2. Versican and versikine expression in TA and diaphragm muscles from wild type and mdx mice. 
Representative images of (A–D) versican and (E–H) versikine immunoreactivity from TA and diaphragm 
muscles from wild type and mdx mice. (I) Quantification of versican immunoreactivity revealed an 
upregulation in TA (* p = 0.001) and diaphragm muscles (# p = 0.0001) from mdx mice when compared to 
wild type mice. (J) Versikine immunoreactivity was similar in mdx and wild type TA or diaphragm 
muscles. White asterisks denote areas of mononuclear infiltration. Immunoreactivity analysis was 
determined from n = 5 wild type mice and n = 5 mdx mice. Scale bar = 100 µm. Error bars = S.E. 
 
Figure 2. Versican and versikine expression in TA and diaphragm muscles from wild type and mdx
mice. Representative images of (A–D) versican and (E–H) versikine immunoreactivity from TA and
diaphragm muscles from wild type and mdx mice. (I) Quantification of versican immunoreactivity
revealed an upregulation in TA (* p = 0.001) and diaphragm muscles (# p = 0.0001) from mdx mice when
compared to wild type mice. (J) Versikine immunoreactivity was similar in mdx and wild type TA or
diaphragm muscles. White asterisks denote areas of mononuclear infiltration. Immunoreactivity
analysis was determined from n = 5 wild type mice and n = 5 mdx mice. Scale bar = 100 µm.
Error bars = S.E.
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Figure 3. Versikine is localised to regenerating myofibres and mononuclear infiltrate, as well as within 
nuclei in mdx TA muscles. Serial cross-sections were stained with versican or versikine and desmin, 
phase images were captured to confirm localisation and tissue orientation. (A–D) Versican was 
localised to interstitium between myofibres. (E–H) Versikine was highly expressed in regenerating 
muscle, as indicated by its association with small desmin positive, centrally nucleated myofibres.  
(I,J) In dystrophic muscle cross-sections, nuclear localisation of versikine, but not versican, was also 
observed. Scale bars = 100 µm. 
2.2. Glucocorticoids Enhance Myoblast Fusion and Myotube Formation 
C2C12 myoblasts were used to investigate glucocorticoid mediated effects on transitional matrix 
synthesis and remodelling during myogenic differentiation. Similar to skeletal muscle development in 
vivo, the myogenic differentiation of C2C12 myoblasts is associated with an upregulation of transitional 
matrix genes, such as V1/V0 Vcan, Adamts1, Adamts5, Adamts15, Pcsk6 [9], Has2 and Hyal2 [8,41]. The 
two-fold increase in the gene expression of the myogenic differentiation marker creatine kinase muscle 
(Ckm) (Figure 4A) and the associated dose dependent increase in total creatine kinase (CK) enzyme 
activity (Figure 4B), indicate that low dose glucocorticoid treatment enhanced myogenic differentiation. 
Essential to myogenic differentiation is the fusion of myoblasts into multinucleated myotubes, a 
multistep process involving migration, alignment, adhesion and membrane coalescence to form nascent 
myotubes [50]. Subsequent growth of these nascent myotubes occurs through the incorporation of 
additional myoblasts via secondary fusion [51,52]. In accordance with previously published findings 
[39,40], the fusion index, which is the proportion of nuclei fused into multinucleated myotubes 
compared to total nuclei, was increased in a dose dependent manner following treatment with 25 nM 
and 100 nM dexamethasone (Figure 4D). Myotube formation and maturation is considered to be a two-
step process, with distinct signaling pathways contributing to the formation of nascent myotubes and 
the growth of mature myotubes [53–55]. Here, nascent myotubes containing 3–4 myonuclei and 
growing, mature myotubes undergoing secondary fusion and containing ≥5 myonuclei, were 
quantified as previously described [9]. In concordance with the fusion index data, there was an increase 
in the number of nascent myotubes (with 3–4 myonuclei) following treatment with 100 nM 
dexamethasone (Figure 4E), as well as a dose dependent increase in the number of mature myotubes 
with ≥5 myonuclei indicating enhanced secondary myoblast fusion (Figure 4F). 
2.3. Glucocorticoids Regulate the Expression of Genes Associated with Transitional Matrix Synthesis and 
Processing during Myogenic Differentiation 
Glucocorticoids may enhance myogenic differentiation by regulating the expression of genes 
associated with transitional matrix synthesis and processing. Specifically, 72 h of treatment with 25 
nM and 100 nM of dexamethasone reduced Tgfb1 mRNA transcript abundance by 50% and 54%, 
respectively (Figure 5A). The decrease in Tgfb1 mRNA transcript abundance was associated with a 
reduction in versican (V0/V1 Vcan) gene expression by up to 56% (Figure 5B) and Has2 gene 
expression by up to 58% (Figure 5C). Has2 is the primary Has gene involved in hyaluronan synthesis 
in skeletal muscle [26]. Adamts1 mRNA transcripts were increased up to three-fold in dexamethasone 
treated C2C12 cells (Figure 5D), whereas Adamts5 or Adamts15 mRNA levels were not affected by 
glucocorticoid treatment (Figure 5E,F). ADAMTS proteoglycanases are synthesised as inactive 
zymogens and become activated upon proteolytic processing by Furin and/or Pace4 [56]. Treatment 
with 25 and 100 nM dexamethasone decreased Pcsk6 (Pace4) gene expression by 65% and 68% 
Figure 3. Versikine is localised to regenerating myofibres and mononuclear infiltrate, as well as
within nuclei in mdx TA muscles. Serial cross-sections were stained with versican or versikine and
desmin, phase images were captured to confirm localisation and tissue orientation. (A–D) Versican
was localised to interstitium between myofibres. (E–H) Versikine was highly expressed in regenerating
muscle, as indicated by its association with small desmin positive, centrally nucleated myofibres.
(I,J) In dystrophic mu cle cross-sections, nuclear localisation of versikine, but not versican, was also
observed. Scale bars = 100 µm.
2.2. Glucocorticoids Enhance Myoblast Fusion and Myotube Formation
C2C12 myoblasts were used to investigate glucocorticoid mediated effects on transitional matrix
synthesis and remodelling during myogenic differentiation. Similar to skeletal muscle development
in vivo, the myogenic differentiation of C2C12 myoblasts is associated with an upregulation of
transitional matrix genes, such as V1/V0 Vcan, Adamts1, Adamts5, Adamts15, Pcsk6 [9], Has2 and
Hyal2 [8,41]. The two-fold increase in the gene expression of the myogenic differentiation marker
creatine kinase muscle (Ckm) (Figure 4A) and the associated dose dependent increase in total
creatine kinase (CK) enzyme activity (Figure 4B), indicate that low dose glucocorticoid treatment
enhanced myogenic differ tiation. Essential to myogenic differentiation is the fusi n f myoblasts
into multi ucleated myotubes, a multistep process inv lvi g m gration, alignment, adhes on and
membrane coalescence to form nascen myotubes [50]. Subs quent growth of these nascent myotubes
occurs through the incorporatio of ad itional myoblasts via secondary fusion [51,52]. In accordance
with previously published findings [39,40], the fusion index, which is the proportion of nuclei fused
into multinucleated myotubes compared to total nuclei, was increased in a dose dependent manner
following treatment with 25 nM and 100 nM dexamethasone (Figure 4D). Myotube formation and
maturation is considered to be a two-step process, with distinct signaling pathways contributing
to the formation of nascent myotubes and the growth of mature myotubes [53–55]. Here, nascent
myotubes containing 3–4 myonuclei and growing, mature myotubes undergoing secondary fusion and
containing ≥5 myonuclei, were quantified as previously described [9]. In concordance with the fusion
index data, there was an increase in the number of nascent myotubes (with 3–4 myonuclei) following
treatment with 100 nM dex methasone (Figure 4E), as well as a dose dependent increase in the number
of mature myotubes with ≥5 myonuclei indicating enhanced secondary myoblast fusion (Figure 4F).
2.3. Glucocorticoids Regulate the Expression of Genes Associated with Transitional Matrix Synthesis and
Processing during Myogenic Differentiation
Glu ocortico ds may en ance myogenic differentiation by regulating the expression of genes
associated with transitional matrix synth sis and processing. Specifically, 72 h of tre tment with 25 nM
and 100 nM of dexamethasone reduced Tgfb1 mRNA transcript abundance by 50% and 54%, respectively
(Figure 5A). The decrease in Tgfb1 mRNA transcript abundance was associated with a reduction in
versican (V0/V1 Vcan) gene expression by up to 56% (Figure 5B) and Has2 gene expression by up to 58%
(Figure 5C). Has2 is the primary Has gene involved in hyaluronan synthesis in skeletal muscle [26].
Adamts1 mRNA transcripts were increased up to three-fold in dexamethasone treated C2C12 cells
(Figure 5D), whereas Adamts5 or Adamts15 mRNA levels were not affected by glucocorticoid treatment
(Figure 5E,F). ADAMTS proteoglycanases are synthesised as inactive zymogens and become activated
upon proteolytic processing by Furin and/or Pace4 [56]. Treatment with 25 and 100 nM dexamethasone
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decreased Pcsk6 (Pace4) gene expression by 65% and 68% respectively (Figure 5G), whilst Pcsk3 (Furin)
mRNA levels were not significantly altered (Figure 5H). Lastly, dexamethasone had no effect on Hyal2
mRNA transcript abundance (Figure 5I), the enzyme necessary for hyaluronan degradation [26].
Int. J. Mol. Sci. 2017, 18, 2629 7 of 22 
 
respectively (Figure 5G), whilst Pcsk3 (Furin) mRNA levels were not significantly altered (Figure 5H). 
Lastly, dexamethasone had no effect on Hyal2 mRNA transcript abundance (Figure 5I), the enzyme 
necessary for hyaluronan degradation [26].  
 
Figure 4. Low dose dexamethasone treatment for 72 h increased myogenic differentiation efficacy in C2C12 
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increased two-fold in cells treated with 25 nM and 100 nM dexamethasone (Dex) (* p < 0.01); (B) CK enzyme 
activity in cell lysates was also increased following treatment with 25 nM (* p = 0.02) and 100 nM 
dexamethasone (# p = 0.01); (C) Dexamethasone (Dex) did not significantly increase myosin heavy chain 1 
(Myh1) mRNA transcripts; (D) Fusion index (FI; * p < 0.001) was greater in C2C12 cells treated with 25 nM 
and 100 nM dexamethasone compared to untreated control cells, and this increase was dose dependent (+ 
p < 0.05); (E) Treatment with 100 nM dexamethasone increased the formation of nascent myotubes 
containing 3–4 myonuclei (* p < 0.001); (F) The number of mature myotubes with ≥5 nuclei was greater in 
cultures treated with 25 nM or 100 nM versus 0 nM dexamethasone (* p = 0.017), and this increase was dose 
dependent (+ p = 0.03); (G) Representative images of C2C12 myotubes. Differentiation C2C12 myoblasts 
were treated with 0 nM dex (A’,D’), 25nM dex (B’,E’) or 100 nM dex (C’,F’) for 72 h. Myotubes were then 
stained with phalloidin for F-actin (red) and DAPI for nuclei (blue). CK enzyme activity was calculated 
from n = 3 biological replicates performed in quadruplicate. The fusion index and myotube number were 
calculated from n = 3 biological replicates performed in duplicate. Gene expression was determined from 
n = 3 biological replicates in triplicate. Scale bar = 200 µm. Error bars = S.E. 
Figure 4. Low dose dexamethasone treatment for 72 h increased myogenic differentiation efficacy in
C2C12 myoblasts. (A) The gene expression of myogenic differentiation marker creatine kinase (Ckm)
was increased two-fold in cells treated with 25 nM and 100 nM dexamethasone (Dex) (* p < 0.01);
(B) CK enzyme activity in cell lysates was also increased following treatment with 25 nM (* p = 0.02)
and 100 nM dexamethasone (# p = 0.01); (C) Dexamethasone (Dex) did not significantly increase myosin
heavy chain 1 (Myh1) mRNA transc ipts; (D) Fusion index (FI; * p < 0.001) was greater in C2C12 cells
treated with 25 nM and 100 nM dexamethason compared to un reated control cells, and this increase
was dose dependent (+ p < 0.05); (E) Treatment with 100 nM dexamethasone increased the formation
of nascent myotubes containing 3–4 myonuclei (* p < 0.001); (F) The number of mature myotubes
with ≥5 nuclei was greater in cultures treated with 25 nM or 100 nM versus 0 nM dexamethasone
(* p = 0.017), and this increase was dose dependent (+ p = 0.03); (G) Representative images of C2C12
myotubes. Differentiation C2C12 myoblasts were treated with 0 nM dex (A’,D’), 25nM dex (B’,E’) or
100 nM dex (C’,F’) for 72 h. Myotubes were then stained with phalloidin for F-actin (red) and DAPI
for nuclei (blue). CK enzyme activity was calculated from n = 3 biological replicates performed in
quadruplicate. The fusion index and myotube number were calculated from n = 3 biological replicates
performed in duplicate. Gene expression was determined from n = 3 biological replicates in triplicate.
Scale bar = 200 µm. Error bars = S.E.
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The effect of glucocorticoids on versican gene expression was confirmed by western blotting. 
Dexamethasone reduced protein levels of full length V0/V1 versican in a dose dependent manner by 
up to 50% (Figure 6B). ADAMTS dependent remodelling of versican during myogenic differentiation 
appeared not to be altered by glucocorticoids, as indicated by similar protein levels of versikine 
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Figure 5. The expression of genes associated with a versican–hyaluronan rich transitional matrix
is modulated by dexamethasone during myoblast differentiation. (A–C) Compared to untreated
control cells, 25 nM or 100 nM dexamethasone treatment decreased Tgfb1 (* p < 0.0001 and * p = 0.0001
respectively), Vcan (* p = 0.005 and * p = 0.0006, respectively) and Has2 mRNA transcripts by
approximately two-fold (* p < 0.0001 and * p = 0.0001, respectively); (D) Adamts1 gene expression was
increased up to three-fold in response to 25 nM and 100 nM dexamethasone treatment (* p = 0.03
and * p < 0.001, respectively); (E,F) Adamts5 and Adamts15 mRNA transcripts were not significantly
increased; (G,H) Pcsk6, but not Pcsk3, mRNA transcripts were decreased approximately two-fold
following treatment with 25 and 100 nM dexamethasone (* p < 0.0001). (I) Hyal2 mRNA levels were not
altered by dexamethasone treatment. Gene expression was determined from n = 3 biological replicates
in triplicate. Error bars = S.E.
The effect of glucocorticoids on versican gene expression was confirmed by western blotting.
Dexamethasone reduced protein levels of full length V0/V1 versican in a dose dependent manner by
up to 50% (Figure 6B). ADAMTS dependent remodelling of versican during myogenic differentiation
appeared not to be altered by glucocorticoids, as indicated by similar protein levels of versikine
following treatment with 25 nM and 100 nM dexamethasone (Figure 6C).
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2.4. Glucocorticoids Rescue Myotube Formation in Differentiating Myoblasts Treated with Exogenous Versican
and Versikine
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i to the positive effects of glucocorti ids n regenerative myogenesis in dystrophic muscles.
To test this hypothesis, differ ntiating C2C12 myoblasts were treated with V1 versican, versikine or
empty v ctor conditioned media supple nted with 0 nM or 100 nM dexamethasone. The addition of
conditioned media made the experimental conditions more challe ging, with greater variability in
fusion between biological r plicates and a blunted response to dexamethasone. Nonetheless, excess
full l ngth or proce sed versican decreased myobla t fusion (m in effect conditioned media; 2-way
GLM ANOVA; * p < 0.001 for versican treated cells and ** p < 0.02 for versikine treated cells; Figure 7C).
Thi decrease in fusion was ameliorated with glucocorticoid tre tment (main effect dexamethasone;
2-way GLM ANOVA; # p < 0.001 for empty vector or versican treated cells and ## p < 0.001 for empty
vector or versikine treated cells; Figure 7C).
As further evidence that versican impairs myoblast fusion, in cells treated with 0 nM
dexamethasone, the versican conditioned media decreased the number of nascent myotubes compared
to empty vector conditioned media (interaction; 2-way GLM ANOVA; * p < 0.001). Following treatment
with 100 nM dexamethasone, the number of nascent myotubes was similar in cells treated with the
versican or empty vector conditioned media (Figure 7D). Versikine had no effect on the number of
nascent myotubes formed (Figure 7D). Unexpectedly, dexamethasone decreased the number of nascent
myotube in cells treated with versikine or empty vector conditioned media (main effect dexamethasone;
2-way GLM ANOVA; # p < 0.01) (Figure 7D).
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Figure 7. Dexamethasone ameliorated the impairment in myogenic differentiation associated with
excess versican. (A,B) Representative western blots of versican, versikine or empty vector (EV)
conditioned media, with the respective images of stain free protein gels or GAPDH as a loading controls;
(C) The addition of versican and versikine conditioned media compromised myoblast differentiation,
as assessed by fusion index (main effect conditioned media; 2-way GLM ANOVA; * p < 0.001 for
versican conditioned media and ** p < 0.02 for versikine condition d me ia relative to cells treated with
the empty vector conditioned media). Whilst, glucocorticoids enhanced myoblast fusi n (mai effect
dexamethasone; 2-way GLM ANOVA; # p < 0.001 for empty vector or versican treated cells and
## p < 0.001 empty vector or versikine treated cells); (D) In the absence of dexamethasone, excess
versican reduced the formation of nascent myotubes (interaction; 2-way GLM ANOVA; * p < 0.001).
In response to 100 nM dexamethasone, the number of nascent myotubes was similar in cells treated with
versican or empty vector conditioned media. Versikine had no effect on nascent myotube formation,
whilst dexamethasone decreased nascent myotube number in cells treated with versikine or empty
vector conditioned media (main effect dexamethasone; 2-way GLM ANOVA; # p < 0.01); (E) Versican
or versikine r duced the number of ature myotube formed per field of view (FOV) (main effect
conditioned media; 2-way GLM ANOVA; * p < 0.0001 for versican treated c lls and ** p < 0.0001
versiki e reated cells), and 100 nM dexam thasone ameliorated this decrease in my tube umber
(main effect dexamethasone; 2-way GLM ANOVA; # p = 0.0092 for empty vector or versican treated
cells and ## p = 0.0061 empty vector or versikine treated cells); (F) Versican or versikine conditioned
media reduced the migration rate of C2C12 myoblasts compared to empty vector conditioned media
(* p = 0.01 and * p = 0.04 respectively); (G) Myoblast cell number was not different following 24 h and
48 h of treatment with versican or versikine conditioned media compared to empty vector conditioned
media; (H) Representative images of C2C12 myotubes. Differentiating C2C12 myoblasts were treated
with 0 nM dex and EV conditioned media (A’,B’), 100 nM dex and EV conditioned media (C’,D’), 0 nM
dex and versican conditioned media (E’,F’), 100 nM dex and versican conditioned media (G’,H’), 0 nM
dex and v rs kine conditioned media (I’,J’), o 100 nM dex an versikine conditioned media (K’,L’)
for 72 h. Myotubes were then stained with phalloidin for F-actin (red) and DAPI for nuclei (blue).
Fusion index (FI) and myotube number were calculated from n = 5 biological replicates performed in
duplicate. Migration rate was measured from n = 5 biological replicates performed in duplicate or
triplicate. Myoblast proliferation was assessed from n = 3 biological replicates performed in 8 wells.
Scale bar = 200 µm. Error bars = S.E.
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With regards to the effects of versican, versikine and glucocorticoids on secondary fusion, the
number of mature myotubes was reduced in cells treated with versican or versikine conditioned
media (main effect conditioned media; 2-way GLM ANOVA; * p < 0.0001 for versican treated cells
and ** p < 0.0001 versikine treated cells; Figure 7E). When differentiating myoblasts were treated with
100 nM dexamethasone, the number of mature myotubes increased (main effect dexamethasone; 2-way
GLM ANOVA; # p = 0.0092 for versican treated cells and ## p = 0.0061 versikine treated cells; Figure 7E).
Alignment of myoblasts is essential for fusion, and this depends on carefully regulated
migration [50,57,58]. Versican is known to modulate cell migration and depending on the biological
context the effects can be stimulatory [59,60] or inhibitory [61]. The effects of versikine on cell migration
have not been well characterised. In C2C12 cells treated with versican or versikine conditioned media
for up to 11 h, myoblast migration rate was reduced by 12% and 13%, respectively (Figure 7F).
Thus, excess versican, both the full-length protein and the cleaved bioactive fragment, may also impair
regenerative myogenesis through a reduction in myoblast migration.
Myoblast viability and number can be a confounding factor in determining the efficacy of
myogenic differentiation. Versican has been shown to increase proliferation in various biological
contexts [62,63], including primary turkey myoblasts [27]. In contrast, versikine has been associated
with apoptosis during interdigital web regression [32]. In actively proliferating C2C12 myoblast
cultures, exogenous versican or versikine had no effect on cell number (Figure 6G).
3. Discussion
In dystrophic skeletal muscles, excess synthesis and inappropriate processing of ECM proteins
lead to degeneration, fibrosis and compromised contractile function [17,64]. Similarities in the
mechanisms of ECM expansion in patients with DMD and mdx mice have been observed,
and contribute to the dystrophic pathology of these muscles [12]. The significance of versican in
the generation and remodelling of a transitional matrix during skeletal muscle development and
regeneration is continuing to gain recognition [8,9,27]. We propose that the carefully regulated synthesis
and processing of a versican rich transitional matrix is also an important factor in differentiating
between successful regenerative myogenesis or degeneration and fibrosis. A better understanding
of versican function in muscular dystrophy is needed if progress is to be made in targeting the
dysregulated ECM, which is a hallmark of DMD pathology.
Here, we report that the expression of full-length versican is increased in dystrophic mdx
diaphragm and hindlimb muscles compared to wild type muscles, with the highest level of versican
expression observed in the more severely affected mdx diaphragm muscles. These observations are in
concordance with human data showing increased versican expression in muscle biopsies from patients
with DMD compared to healthy controls, as assessed by immunohistochemistry [65] and microarray
gene expression analysis [66]. Furthermore, deposition of chondroitin sulphate GAG side chains is
upregulated in DMD [15], and V0/V1 versican is a significant source of chondroitin sulphate GAG
chains in skeletal muscle. V0 versican is the most highly glycosylated isoform, followed by the V1
variant [67]. Versican is secreted and synthesised by activated satellite cells and myoblasts [27,68],
newly formed myotubes [28], inflammatory cells [69] and fibroblasts [70].
Versican is transiently upregulated in myoblasts and newly formed myotubes during development
and regeneration [28,71], whilst in healthy, mature skeletal muscle full length versican expression
is quite low. Versican remodelling has been implicated in various developmental processes,
and remodelling by specific ADAMTS proteoglycanases generates versikine [19,32]. Interestingly,
in mdx TA muscles, versikine immunoreactivity was associated with small, recently regenerated
myofibres. Furthermore, in dystrophic muscles, the nuclear localisation of versikine was observed
in both muscle fibres and in mononuclear infiltrate. This is in line with observations by Carthy et al.,
who using the same anti-DPEAAE neo-epitope antibody (ThermoFisher Scientific, PA1-1748A,
Waltham, MA, USA) detected nuclear versikine staining in vascular smooth muscle cells and
proposed a potential role in mitotic spindle organization during cell division [63]. Versikine is further
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degraded by various ECM proteases. This hypothesis is supported by the observation that versikine
immunoreactivity in developing mouse hindlimb muscles at E13.5 days is much higher than in mature
muscles at 3 weeks of age [9]. This further degradation of versikine may account for the lack of
difference in protein levels between diaphragm and TA muscles from mdx and wild type mice, despite
increased V0/V1 versican expression.
In vivo, centrally nucleated fibres are indicative of recent damage and repair, with myoblast
fusion being essential for effective regeneration. In diaphragm muscles from mdx mice, the proportion
of centrally nucleated fibres is much lower, up to 2–3 folds, when compared to dystrophic TA
muscles [48,72]. We hypothesise that excess versican accumulation contributes to the impaired
regenerative capacity of mdx diaphragm muscles. As such, we propose that versican reduction
could be a potential strategy to ameliorate the pathology of dystrophic muscles. In vitro evidence that
processing of versican by ADAMTS5 or -15 facilitates myoblast fusion supports this hypothesis [9].
Furthermore, others have shown that the formation of multinucleated myotubes is associated with
a reduction in chondroitin sulphate GAG sidechains, which also suggests a potential role for versican
processing [73]. It is worth noting that versikine does not contain chondroitin sulphate GAG side
chains [74].
Glucocorticoids improve muscle function in patients with DMD through various cellular
mechanisms [36,75,76]. Of particular interest, are the effects of glucocorticoids on ECM synthesis and
remodelling [77], on TGF-β [78] and TGF-β centred signalling networks, as these are highly relevant
to regenerative myogenesis and fibrosis [12]. Our observation of a concentration dependent increase
in myoblast fusion and myotube formation following low dose, 25 nM and 100 nM, dexamethasone
treatment is in concordance with a number of studies reporting positive effects of glucocorticoids
on myogenesis in vitro [39,40] and muscle regeneration in vivo [12,37]. In contrast to our findings,
Ma et al. [79] reported inhibition of myogenic differentiation of C2C12 and primary mouse myoblasts
following glucocorticoid treatment through the activation of glycogen synthase kinase 3β (GSK-3β).
However, the concentration of dexamethasone used (10 µM) was 100–400 folds higher than our low
dose treatment [79]. Furthermore, with lower concentrations of 10 nM and 100 nM dexamethasone,
no significant decrease in myogenin or myosin heavy chain protein expression was reported, whilst the
fusion index was not assessed [79].
The increase in myotube formation following glucocorticoid treatment was associated with
decreased V0/V1 versican protein and V0/V1 Vcan, Has2 and Tgfb1 mRNA transcript abundance.
This reduction in Tgfb1 gene expression in response to glucocorticoids is in agreement with
in vivo studies in mdx mice [12,78], and in vitro studies using hepatic stellate cells [80] and fetal
lung fibroblasts [81]. In differentiating myoblasts, glucocorticoids appear to have specific effects
on the various Adamts proteoglycanase isoforms and genes involved in ADAMTS activation,
as dexamethasone treatment was also associated with an increase in Adamts1, but not Adamts5 and -15,
gene expression, as well as a decrease in Pcsk6 (but not Pcsk3) mRNA transcript abundance. Altogether,
these data suggest that glucocorticoids may attenuate the synthesis of a transitional, pericellular
matrix, thus facilitating membrane coalescence during fusion in differentiating C2C12 myoblasts [9].
The effects of glucocorticoids on a versican and hyaluronan rich transitional matrix have been described
in other biological contexts. Specifically, glucocorticoid induced skin atrophy is associated with
reduced proteoglycan [82] and hyaluronan synthesis [44,45]. Glucocorticoids have also been reported
to decrease versican expression in cultured rat mesangial cells and airway fibroblasts [43,79].
Myoblast fusion was reduced when differentiating C2C12 myoblasts were treated with versican
conditioned media, supporting our hypothesis that excess versican impairs regenerative myogenesis.
This decrease in myoblast fusion was ameliorated, but not fully reversed, with dexamethasone.
Versikine conditioned media also impaired myoblast fusion, and this impairment was also ameliorated
by glucocorticoid treatment. Hyaluronan can bind to versican, and perhaps also versikine, via the G1
N-terminus link module [25], thus contributing to pericellular matrix expansion. We have previously
shown that expansion and inadequate processing of a versican–hyaluronan rich pericellular matrix
Int. J. Mol. Sci. 2017, 18, 2629 13 of 22
impairs myoblast fusion and myotube formation [9]. This decrease in fusion was interrogated
further by quantifying the number of nascent and mature myotubes following versican, versikine
and/or dexamethasone treatment. An excess of versican decreased the number of nascent myotubes,
and this decrease was ameliorated by dexamethasone treatment. Whereas, an excess of versikine did
not compromise nascent myotube formation. Myotube hypertrophy and nuclear accretion occurs
via secondary fusion, which involves distinct signalling pathways compared to the formation of
nascent myotubes [51]. Excess versican and versikine reduced the formation of mature myotubes.
Dexamethasone rescued this impairment and increased the number of mature myotubes formed.
Excess versican or versikine may impair myoblast migration, thus potentially contributing to the
observed decrease in myoblast fusion and myotube number. The effects of versican on cell migration
are context dependent, as during development, versican has been suggested to deter muscle cell
migration and thus contribute to the patterning of the limb skeleton and joints [83]. The underlying
mechanism by which versican and versikine regulate cell migration during myogenesis remains to be
determined, but may involve CD44 signalling [57,84,85]. Full length versican, through its chondroitin
sulphate side chains, can bind to the CD44 receptor directly [84]. Through interactions with the link
module on the G1 domain, versican and versikine bind hyaluronan [19], which is also a known ligand
for the CD44 receptor [85]. Altogether, these observations suggest a novel mechanism by which excess
versican could compromise regenerative myogenesis in muscular dystrophy.
We propose that excess accumulation of versican in dystrophin-deficient muscles compromises
regeneration and exacerbates fibrosis. Dadgar et al. [12] have recently confirmed that TGF-β centred
signalling networks are key drivers for fibrosis and failed regeneration in muscular dystrophy.
TGFβ stimulates V0/V1 versican synthesis in various biological contexts [59,86–88]. Furthermore,
the interaction between TGF-β and versican is bidirectional, with versican potentiating TGFβ
signalling [89] and regulating bioavailability [90]. When dystrophic mdx mice were treated with
glucocorticoids, these TGF-β centered networks were suppressed and the dystrophic pathology was
ameliorated [12]. Therefore, our in vitro observations that glucocorticoids reduce V0/V1 versican
(Vcan) and Tgfb1 expression in differentiating myoblasts highlight the relevance of these genes to
regenerative myogenesis, especially in the context of dystrophy.
To fully characterise the role of versican in regenerative myogenesis in dystrophic skeletal muscles
in vivo studies using genetic and/or pharmacological approaches are needed. The advantage of such
in vivo studies is that they will allow the effects of versican on muscle repair and function to be
investigated in the presence of an expanded ECM and increased inflammation. This is important,
given the emerging role of versican [91,92] and versikine [33] in regulating inflammation in various
biological contexts.
4. Materials and Methods
4.1. Mouse Models
All animal studies were approved by the La Trobe University and Deakin University Animal
Ethics Committees, in accordance with the National Health and Medical Research Council (NH&MRC)
guidelines, under the ethics numbers of AEC16-08 for La Trobe University (approved: 1 January 2016),
and G35-2013 and A79/2011 (approved: 1 January 2015 and 1 January 2012, respectively) for Deakin
University. Between 3 and 6 months of age, C57BL/10 (wild type) and mdx mice were deeply
anaesthetised with sodium pentobarbitone (60 mg/kg) and killed by cardiac excision. TA and
diaphragm muscles were collected for immunohistochemical analysis by embedding the blotted
tissues in optimal cutting temperature compound (OCT) and freezing in thawing 2-methylbutane
cooled in liquid nitrogen. TA and diaphragm muscles were also snap frozen in liquid nitrogen for
gene expression analysis.
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4.2. Skeletal Muscle Immunohistochemistry and Histology
Transverse frozen sections were cut from the mid-belly of the TA or diaphragm muscle strips at
a thickness of 8 µm, mounted on slides and stored at −80 ◦C until analysis. Immunohistochemistry
for ADAMTS1 (Origene, TA317919, Rockville, MD, USA), ADAMTS5, ADAMTS15 (Abcam, ab45047,
Cambridge, MA, USA), V0/V1 versican (anti-GAGβ; Merck Millipore, AB1033, Bayswater, VIC,
Australia) or versikine (anti-DPEAAE neo-epitope; Thermo Fisher Scientific, PA1-1748A, Scoresby, VIC,
Australia) were performed as previously described [9,32]. An anti-desmin rabbit polyclonal antibody
(Abcam, ab15200, Cambridge, MA, USA) together with an anti-rabbit Alexa Fluor 488 secondary
antibody (Thermo Fisher Scientific, R37116,) were used to detect myoblasts and newly regenerated
myofibres [93,94]. Representative wild type and mdx TA and diaphragm muscle cross-sections were H
and E stained for muscle architecture, and wheat germ agglutinin to assess fibrosis [95]. For analysis of
V0/V1 versican and versikine immunoreactivity, four non-overlapping representative digital images
were captured with a confocal microscope of each muscle section at 600× magnification (Olympus
Fluoview FV10i) and analysed for area of immunoreactivity using Image-Pro Plus software (Version 7,
Media Cybernetics, Silver Spring, MD, USA).
4.3. Cell Culture and Expression Constructs
HEK293T cells were grown in Dulbecco’s Modified Eagle Medium (DMEM; 25 mM glucose)
containing 10% fetal bovine serum (FBS) in atmospheric O2 and 5% CO2 at 37 ◦C. Cells were transfected
using Lipofectamine 2000 (Thermo Fisher Scientific) with constructs encoding the V1 versican
construct (kindly provided by Dieter Zimmermann), the bioactive G1-DPEAAE versikine fragment was
produced by the insertion of a stop codon in the V1 versican construct after the Glu441-Ala442 peptide
bond cleavage site [32], and empty vector control (pcDNA3.1MycHisA+ (Thermo Fisher Scientific)).
Serum-free conditioned medium was collected for use in the myoblast differentiation experiments,
as previously described [9], and underwent western blotting for confirmation of V1 versican and
versikine protein expression. C2C12 myoblasts, a well characterized in vitro model of myoblast fusion
and regenerative myogenesis [96,97], were maintained in growth medium (25 mM glucose DMEM
plus 10% FBS) in atmospheric O2 and 5% CO2 at 37 ◦C.
4.4. Glucocorticoid Treatment of Differentiating C2C12 Cells
To determine the effects of glucocorticoids on myoblast differentiation, cells were seeded at
25,000 cells/cm2; in duplicate wells for fusion index determination, and in triplicate wells for gene and
protein expression and creatine kinase activity analyses. Following 48 h of proliferation (and at >90%
confluence), myoblasts were treated with differentiation medium (25 mM glucose DMEM plus 2%
horse serum (HS)) supplemented with 0 nM, 25 nM or 100 nM dexamethasone (Prednisolone F,
Sigma-Aldrich, D1756, Castle Hill, NSW, Australia) for 72 h (refreshed every 24 h). The latter is
a low glucocorticoid concentration which has been shown to increase myoblast fusion efficiency
in vitro [39]. Following this, the cells were harvested for biochemical analyses (see below) or fixed
with 4% paraformaldehyde, and stained with Alexa-Fluor 568 phalloidin (1:50; Life Technologies) and
DAPI (1:20; Life Technologies) for 20 min.
Fusion index was used as a proxy readout to assess myoblast differentiation efficacy. Nascent
myotubes with 3–4 myonuclei and mature myotubes with≥5 myonuclei were quantified, as previously
described [9,50]. For the fusion index, 3 biological replicates (at different passages) in duplicate were
performed. For the control cells treated with 0 nM dexamethasone, the % fusion index for each of the
three biological replicates ranged from 17–20. For each experimental condition and biological replicate,
8897 ± 222 nuclei were counted to assess fusion index and 270 ± 23 myotubes were classified and
counted to assess myotube maturation.
The fusion index data are supported by gene markers of myoblast differentiation and
a commercially available creatine kinase enzyme activity assay kit, as per manufacturer’s instructions
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(ab155901, Abcam) [98]. The cell lysates from the creatine kinase enzyme activity assay were also used
for analysis of versican and versikine protein expression.
4.5. RNA Extraction, Reverse Transcription, and Quantitative RT-PCR
Cells were harvested in triplicate wells, collected in TRIzol (Sigma-Aldrich) and stored at −80 ◦C.
TA and diaphragm muscles were mechanically homogenised in TRIzol. Upon thawing, RNA was
extracted and 1 µg of total RNA was reverse-transcribed using an iScript cDNA synthesis kit
(Bio-Rad, Gladesville, NSW, Australia). Quantitative RT-PCR was performed using iQ SYBR Green
Supermix (Bio-Rad) and oligonucleotide primers for the murine genes of interest (Table 1). Relative
changes in mRNA levels to untreated myotubes were calculated using the ∆Ct method. Real time
data was normalised to cDNA content, as determined using a Quant-iT Oligreen ssDNA reagent kit
(Life Technologies).
Table 1. List of primer sequences used for quantitative RT-PCR.
Accession Number Name Forward Sequence (5′-3′) Reverse Sequence (5′-3′)
NM_009621.5 Adamts1 CCTGTGAAGCCAAAGGCATTG TGCACACAGACAGAGGTAGAGT
NM_011782.2 Adamts5 GCTACTGCACAGGGAAGAGG GCCAGGACACCTGCATATTT
NM_001329420.1 Adamts15 GCTCATCTGCCGAGCCAAT CAGCCAGCCTTGATGCACTT
NM_007710.2 Ckm 1 CCGTGTCACCTCTGCTGCTG TCCTTCATATTGCCTCCCTTCTCC
XM_011250822.2 Pcsk3 2 CAGCGAGACCTGAATGTGAA CAGGGTCATAATTGCCTGCT
NM_008216.3 Has2 GGGACCTGGTGAGACAGAAG ATGAGGCAGGGTCAAGCATA
XM_006511645.3 Hyal2 AGCCGCAACTTTGTCAGTTT GAGTCCTCGGGTGTATGTGG
XM_017314318.1 Myh1 3 GCTCAAAGCCCTGTGTTACC CATAGACGGCTTTGGCTAGG
NM_001291184.1 Pcsk6 4 ATTTCCCCAACCTCGTCTCT AGCTGAGTCCTTGCCACCTA
NM_011577.2 Tgfb1 GCCTGAGTGGCTGTCTTTTGA CACAAGAGCAGTGAGCGCTGAA
NM_001081249.1 (V0)
V0/V1 Vcan 5 ACCAAGGAGAAGTTCGAGCA CTTCCCAGGTAGCCAAATCANM_019389.2 (V1)
1 Creatine kinase muscle, 2 Furin, 3 Myosin heavy chain 1 (fast IIx/d isoform), 4 Pace4, 5 Versican (primers detect
the V0 and V1 isoforms).
4.6. Versican or Versikine Treatment and C2C12 Myoblast Differentiation
To assess the effects of glucocorticoids on myotube formation in the presence of excess versican
or versikine, C2C12 cells were seeded at 20,000 cells/cm2 in duplicate wells, 24 h or 48 h later the
differentiation medium was added for 4 or 3 days, respectively. Depending on the experimental
conditions, the differentiation medium was supplemented with 0 nM or 100 nM dexamethasone
and serum-free versican, versikine or empty vector conditioned media (diluted 1:4; refreshed daily).
Fusion index and myotube number were determined and analysed as described above. Five biological
replicates (at different passages) in duplicate were performed, with a total of 3156 ± 96 nuclei and
110± 3 myotubes counted per experimental condition for each biological replicate. For the control cells
treated with empty vector conditioned media and 0 nM dexamethasone, the % fusion index for each of
three biological replicates ranged from 19–27%. This greater variability in % fusion compared to the
dexamethasone dose response experiments reflects the more challenging experimental conditions.
4.7. Versican or Versikine Treatment and C2C12 Myoblast Migration and Proliferation
To assess the specific effects of versican and versikine on myoblast migration, a process essential
for effective differentiation [50,57], cells were seeded at 8500 cells/cm2 in triplicate wells and 72 h later
(when 100% confluent) a scratch wound assay was performed [58]. Growth media was supplemented
with serum-free versican, versikine or empty vector conditioned media (diluted 1:4) for up to 11 h.
To determine migration rate, digital images (three per well) were digitally captured at 0 h, 6 h and
11 h post-wounding. The distance between the edges of the scratches was measured using Adobe
Photoshop CS6 (Adobe Systems), with the migration rate calculated in pixels/min.
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To assess the effects of versican and versikine on myoblast proliferation, cells were seeded
at 10,000 cells/cm2 in growth media, supplemented with serum-free versican, versikine or empty
vector conditioned media (diluted 1:4; refreshed daily) for 48 h. Myoblast number was assessed
using the WST-1 cell proliferation reagent (Roche Life Science, Sydney, NSW, Australia), as per the
manufacturer’s directions.
4.8. Western Blot
To improve detection by the anti-V0/V1 versican antibody, the GAG side chains were removed.
Specifically, 1 µL of chondroitinase ABC (Seikagaku, Tokyo, Japan) was added to the versican
conditioned media and to the cell lysates from the creatine kinase enzyme assay for 2 h at 37 ◦C.
The serum free conditioned media containing versikine was subjected to the western blotting as
described by Dancevic et al. [30]. The versican conditioned media and C2C12 cell lysates underwent
SDS-PAGE using pre-cast Mini-PROTEAN TGX Stain-Free Protein Gels (Bio-Rad), which were
transferred onto PVDF membranes. Proteins were visualised by chemiluminescence on a Chemidoc
XRS+ (Bio-Rad) and analysed using ImageLab software (Bio-Rad). Versican and versikine protein levels
were normalised to total optical density of all protein bands on the TGX Stain-Free Protein Gel. Primary
antibodies used were anti-GAGβ (V0/V1 versican) (1:200, Merck Millipore), anti-V0/V1 DPEAAE
neo-epitope (versikine) (1:1000, Thermo Fisher Scientific, PA1-1748A), and anti-GAPDH (1:10,000,
Merck Millipore, AB1033). Secondary antibodies used were peroxidase AffiniPure goat anti-rabbit IgG
(1:5000, Jackson ImmunoResearch Laboratories) and anti-mouse IR680 (1:10,000, Sigma Aldrich).
4.9. Statistical Analyses
For the versican gene expression data, 2-way general linear model (GLM) ANOVA was performed
with the factors being muscle type (diaphragm versus TA) and strain (C57BL/10 versus mdx). For the
quantitation of versican and versikine immunoreactivity in TA and diaphragm muscles from mdx
and wild type mice, independent t-tests were used to assess differences in immunoreactivity between
C57BL/10 and mdx mice for a given muscle type. For the cell culture experiments, independent t-tests,
1-way or 2-way GLM ANOVA were performed as appropriate and followed by Tukey’s post-hoc
analysis where required. All data are presented as mean ± S.E. and were considered statistically
significant when p < 0.05.
Acknowledgments: The authors wish to thank Alister Ward for critical reading of this manuscript. This work
was supported, in whole or in part, by the Molecular and Medical Research SRC (Strategic Research Centre) and
The Financial Markets Foundation for Children Grant 162-2010 (to Daniel McCulloch and Nicole Stupka).
Author Contributions: Nicole Stupka, Natasha McRae and Daniel McCulloch conceived and coordinated the
study. Natasha McRae and Nicole Stupka wrote the paper. Chris Van der Poel and Nicole Stupka performed all
mouse experiments and prepared the muscle cryosections. Natasha McRae performed experiments shown
in Figures 1–7, analysed most data presented throughout, and prepared all figures and tables throughout
the manuscript. Leonard Forgan and Bryony McNeill contributed to analysis of data presented in Figure 2I,J.
Alex Addinsall contributed to experiments shown in Figure 6C,D. All authors reviewed the results, and approved
the final version of the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ADAMTS A disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats
CSPG Chondroitin sulphate proteoglycan
CK Creatine kinase
Ckm Creatine kinase muscle
Dex Dexamethasone
DMEM Dulbecco’s modified eagle medium
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FOV Field of view
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GSK-3β Glycogen synthase kinase-3β
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Myh1 Myosin heavy chain 1
OCT Optimum cutting temperature
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TGF-β Transforming growth factor-β
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